Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

被引:32
|
作者
Gaglio, Paul [1 ,2 ]
Marfo, Kwaku [1 ,2 ]
Chiodo, Joseph, III [3 ]
机构
[1] Montefiore Med Ctr, Div Hepatol, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Otsuka Amer Pharmaceut Inc, Med Sci Liaison, Rockville, MD USA
关键词
Arginine vasopressin; MELD score; Portal hypertension; Vasopressin receptor antagonists; SERUM SODIUM CONCENTRATION; V-2 RECEPTOR ANTAGONIST; PRETRANSPLANT HYPONATREMIA; HEPATIC-ENCEPHALOPATHY; RISK-FACTORS; ASCITES; MULTICENTER; SATAVAPTAN; CONIVAPTAN; MANAGEMENT;
D O I
10.1007/s10620-012-2276-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hyponatremia is common in patients with cirrhosis and portal hypertension, and is characterized by excessive renal retention of water relative to sodium due to reduced solute-free water clearance. The primary cause is increased release of arginine vasopressin. Hyponatremia is associated with increased mortality in cirrhotic patients, those with end-stage liver disease (ESLD) on transplant waiting lists, and, in some studies, posttransplantation patients. Clinical evidence suggests that adding serum sodium to model for ESLD (MELD) scoring identifies patients in greatest need of liver transplantation by improving waiting list mortality prediction. Hyponatremia is also associated with numerous complications in liver disease patients, including severe ascites, hepatic encephalopathy, infectious complications, renal impairment, increased severity of liver disease in cirrhosis, and increased hospital stay and neurologic/infectious complications posttransplant. Vasopressin receptor antagonists, which act to increase free water excretion (aquaresis) and thereby increase serum sodium concentration, have been evaluated in patients with hypervolemic hyponatremia (including cirrhosis and heart failure) and euvolemic hyponatremia (SIADH). Tolvaptan, a selective vasopressin V-2-receptor antagonist, is the only oral agent in this class approved for raising sodium levels in hypervolemic and euvolemic hyponatremia. The SALT trials showed that tolvaptan treatment rapidly and effectively resolved hyponatremia in these settings, including cirrhosis, and it has been shown that this agent can be safely and effectively used in long-term treatment. Fluid restriction should be avoided during the first 24 h of treatment to prevent overly rapid correction of hyponatremia, and tolvaptan should not be used in patients who cannot sense/respond to thirst, anuric patients, hypovolemic patients, and/or those requiring urgent intervention to raise serum sodium acutely.
引用
收藏
页码:2774 / 2785
页数:12
相关论文
共 50 条
  • [31] The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials
    Yan, Long
    Xie, Feng
    Lu, Jiongjiong
    Ni, Qingqiang
    Shi, Changying
    Tang, Caixi
    Yang, Jiamei
    BMC GASTROENTEROLOGY, 2015, 15
  • [32] Efficacy and safety of conivaptan, a vasopressin via- and v2-receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia
    Verbalis, Joseph G.
    Rosansky, Steven
    Wagoner, Lynne E.
    McNutt, Bruce
    Yan, Bo
    CHEST, 2007, 132 (04) : 562S - 562S
  • [33] The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials
    Long Yan
    Feng Xie
    Jiongjiong Lu
    Qingqiang Ni
    Changying Shi
    Caixi Tang
    Jiamei Yang
    BMC Gastroenterology, 15
  • [34] Satavaptan -: Vasopressin V2 antagonist treatment of hyponatremia treatment of cirrhotic ascites
    Revill, P.
    Serradell, N.
    Bolos, J.
    Bayes, M.
    DRUGS OF THE FUTURE, 2007, 32 (01) : 26 - 36
  • [35] Model for End-Stage Liver Disease and liver cirrhosis-related complications
    Luis Calzadilla Bertot
    Eduardo Vilar Gomez
    Linnet Alonso Almeida
    Enrique Arus Soler
    Luis Blanco Perez
    Hepatology International, 2013, 7 : 347 - 355
  • [36] Tolvaptan.: Treatment of heart failure, vasopressin V2 antagonist.
    Sorbera, LA
    Castañer, J
    Bayés, M
    Silvestre, J
    DRUGS OF THE FUTURE, 2002, 27 (04) : 350 - 357
  • [37] Model for End-Stage Liver Disease and liver cirrhosis-related complications
    Calzadilla Bertot, Luis
    Vilar Gomez, Eduardo
    Alonso Almeida, Linnet
    Arus Soler, Enrique
    Blanco Perez, Luis
    HEPATOLOGY INTERNATIONAL, 2013, 7 (02) : 347 - 355
  • [38] Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia:: A randomized trial
    Gines, Pere
    Wong, Florence
    Watson, Hugh
    Milutinovic, Slobodan
    del Arbol, Luis Ruiz
    Olteanu, Dan
    HEPATOLOGY, 2008, 48 (01) : 204 - 213
  • [39] Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure
    Takagi, Koji
    Sato, Naoki
    Ishihara, Shiro
    Iha, Hayano
    Kobayashi, Noriyuki
    Ito, Yusuke
    Nohara, Tsuyoshi
    Ohkuma, Satoru
    Mitsuishi, Tatsuya
    Ishizuka, Atsushi
    Shigihara, Shota
    Sone, Michiko
    Nakama, Kenji
    Tokuyama, Hideo
    Omote, Toshiya
    Kikuchi, Arifumi
    Nakamura, Shunichi
    Yamamoto, Eisei
    Ishikawa, Masahiro
    Amitani, Kenichi
    Takahashi, Naoto
    Maruyama, Yuji
    Imura, Hajime
    Shimizu, Wataru
    JOURNAL OF CARDIOLOGY, 2020, 76 (05) : 499 - 505
  • [40] A novel oral vasopressin V2 receptor antagonist for the treatment of acute decompensated heart failure and hyponatremia
    Jennings, Douglas L.
    Kalus, James S.
    FORMULARY, 2008, 43 (07) : 236 - +